Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

NCT05565976 is registered in ClinicalTrials.gov with Jaime Daniel Mondragon as lead sponsor.

NCT NCT05565976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05565976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Lead sponsor
Jaime Daniel Mondragon
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 1, 2020
Completion date
July 1, 2025
Enrollment
270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, vascular, metabolic syndrome, mild cognitive impairment, stroke, ischemic